- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Frankfurt | 90,480 | 04.06.24 19:29:32 | +0,170 | +0,19% | 0,000 | 0,000 | 90,130 | 90,310 |
|
REGENERON PHARMAC.DL-,001 | 881535 | Frankfurt | 912,600 | 04.06.24 17:25:05 | +3,400 | +0,37% | 0,000 | 0,000 | 903,200 | 909,200 |
